This technology is particularly applicable to nephrology, in which the genetic basis of multiple disorders has been identified, but single-gene testing remains impractical given broad, overlapping clinical phenotypes. We describe two cases of nephronophthisis mutations identified via whole exome sequencing. Case Report: The first, a case of a 29 year

old female Maraviroc cell line who was diagnosed with juvenile nephronophthisis on renal biopsy at 14 years old. She subsequently underwent deceased-donor kidney transplantation at 18years. She is a product of consanguineous parents. Her mother and brother also have end stage renal failure. The family underwent single-gene testing of the UMOD gene, as a possible autosomal dominant cause of their renal failure, with no pathologic mutation identified. Our patient subsequently underwent whole R788 cost exome sequencing, as part of a research cohort of Australian patients investigated for a genetic cause for their kidney disease. Sequencing revealed a novel homozygous splice-site mutation within NPHP1 (NM_000272.3:c.1884+1G>T).The second is a case of a 3 year old boy who presented with hepatosplenomegaly

and renal failure at 18 months old, and is now dialysis dependent. He had no significant family history. Whole exome sequencing tuclazepam identified a reported homozygous missense mutation within NPHP3 (NM_153240.4:c.1928C>T:p.Pro643Leu). Conclusions: We have utilised massively parallel sequencing to identify both a novel and known nephronophthisis mutation in separate cases, and importantly these findings have guided treatment, transplantation and family planning for these patients. These experiences highlight the benefits of utilising this technology to

identify a genetic diagnosis in patients with renal disease. 203 ASSESSMENT OF MEDICATION AWARENESS AND THE UTILITY OF MEDICATION CARDS IN CHRONIC HAEMODIALYSIS PATIENTS H NANDAKOBAN, YM KUANG, M SURANYI, A MAKRIS Renal Unit, Liverpool Hospital, Sydney, NSW, Australia Aim: To determine the factors contributing to medication awareness for chronic haemodialysis (HD) patients and determine the utility of medication cards in improving medication awareness. Background: Patients on HD often have several chronic health issues and are subject to polypharmacy. Errors in medication prescription and ingestion can lead to morbidity. There is little information about prescribed medication understanding in HD patients. Medication cards may improve patient understanding of their medications.